BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 19361975)

  • 1. Optimal timing of use reduction vs. harm reduction in a drug epidemic model.
    Caulkins JP; Tragler G; Wallner D
    Int J Drug Policy; 2009 Nov; 20(6):480-7. PubMed ID: 19361975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Casting light on harm reduction: introducing two instruments for analysing contradictions between harm reduction and 'non-harm reduction'.
    Jourdan M
    Int J Drug Policy; 2009 Nov; 20(6):514-20. PubMed ID: 19349155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalization and harm reduction: research avenues and policy agendas.
    Erickson PG; Hathaway AD
    Int J Drug Policy; 2010 Mar; 21(2):137-9. PubMed ID: 20022234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Policy and the Public Good: a summary of the book.
    Drugs and Public Policy Group
    Addiction; 2010 Jul; 105(7):1137-45. PubMed ID: 20642498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs.
    Ritter A; Cameron J
    Drug Alcohol Rev; 2006 Nov; 25(6):611-24. PubMed ID: 17132577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV infection among intravenous drug users: epidemiology and risk reduction.
    Des Jarlais DC; Friedman SR
    AIDS; 1987 Jul; 1(2):67-76. PubMed ID: 3130084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of joined-up HIV harm reduction and multidrug resistant tuberculosis control programmes in Estonia: System dynamics simulation model.
    Atun RA; Lebcir RM; McKee M; Habicht J; Coker RJ
    Health Policy; 2007 May; 81(2-3):207-17. PubMed ID: 16854499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coke and smack at the drugstore: harm reductive drug legalization: an alternative to a criminalization society.
    Mamber N
    Cornell J Law Public Policy; 2006; 15(3):619-64. PubMed ID: 17593583
    [No Abstract]   [Full Text] [Related]  

  • 9. Strengthening drug policy and practice through ethics engagement: an old challenge for a new harm reduction.
    Irwin KS; Fry CL
    Int J Drug Policy; 2007 Mar; 18(2):75-83. PubMed ID: 17689348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods for comparing drug policies--the utility of composite drug harm indexes.
    Ritter A
    Int J Drug Policy; 2009 Nov; 20(6):475-9. PubMed ID: 19356915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing prevalence of HIV, and persistent high-risk behaviours among drug users in Bangladesh: need for a comprehensive harm reduction programme.
    Islam MM; Conigrave KM
    Drug Alcohol Rev; 2007 Jul; 26(4):445-54. PubMed ID: 17564883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keeping them connected--reducing drug-related harm in Australian schools from a Catholic perspective.
    Norden P
    Drug Alcohol Rev; 2008 Jul; 27(4):451-8. PubMed ID: 18584402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Putting at risk what we know: reflecting on the drug-using subject in harm reduction and its political implications.
    Moore D; Fraser S
    Soc Sci Med; 2006 Jun; 62(12):3035-47. PubMed ID: 16413645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fentanyl use among street drug users in Toronto, Canada: behavioural dynamics and public health implications.
    Firestone M; Goldman B; Fischer B
    Int J Drug Policy; 2009 Jan; 20(1):90-2. PubMed ID: 18508256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theorizing "Big Events" as a potential risk environment for drug use, drug-related harm and HIV epidemic outbreaks.
    Friedman SR; Rossi D; Braine N
    Int J Drug Policy; 2009 May; 20(3):283-91. PubMed ID: 19101131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avoiding counterproductive results: an experimental pretest of a harm reduction intervention on attitude toward party drugs among users and nonusers.
    Whittingham JR; Ruiter RA; Bolier L; Lemmers L; Van Hasselt N; Kok G
    Subst Use Misuse; 2009; 44(4):532-47. PubMed ID: 19242864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving health and social care relationships for harm reduction.
    Allman D; Myers T; Schellenberg J; Strike C; Cockerill R; Cavalieri W
    Int J Drug Policy; 2007 May; 18(3):194-203. PubMed ID: 17689366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partnerships and communities in English drug policy: the challenge of deprivation.
    Macgregor S; Thickett A
    Int J Drug Policy; 2011 Nov; 22(6):478-90. PubMed ID: 21890338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newspaper coverage of drug policy: an analysis of pre-election reporting of the Greens' drug policy in Australia.
    Jones SC; Hall D; Cowlin F
    Drug Alcohol Rev; 2008 Jan; 27(1):5-11. PubMed ID: 18034376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The issue of harm reduction in Polish legislation concerning drug addiction. A comparative study].
    Sobeyko J
    Ann Acad Med Stetin; 2008; 54(2):119-31. PubMed ID: 19374242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.